Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu

[Image: see text] There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin’s lymphoma radioimmunotherapy. Therefore, many researchers have modified this monoclonal antibody by...

Descripción completa

Detalles Bibliográficos
Autores principales: Karczmarczyk, Urszula, Sawicka, Agnieszka, Garnuszek, Piotr, Maurin, Michał, Wojdowska, Wioletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109692/
https://www.ncbi.nlm.nih.gov/pubmed/35442675
http://dx.doi.org/10.1021/acs.jmedchem.1c02044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109692/
https://www.ncbi.nlm.nih.gov/pubmed/35442675
http://dx.doi.org/10.1021/acs.jmedchem.1c02044

Ejemplares similares